InvestorsHub Logo
Followers 19
Posts 1039
Boards Moderated 0
Alias Born 04/18/2018

Re: FI101 post# 35385

Tuesday, 06/29/2021 9:23:40 AM

Tuesday, June 29, 2021 9:23:40 AM

Post# of 35961
Onclive.com has PH II trial results for the study of patients with advanced liver cancer not a cure but stabilized the tumor growth for extended time period.

The first-in-class prodrug, mipsagargin (G-202), showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.

https://www.onclive.com/view/mipsagargin-demonstrates-clinical-benefit-in-patients-with-advanced-hcc